Merck discontinues Recarbio antibiotic amid superbug resistance concerns

Merck has discontinued Recarbio, a key antibiotic in the U.S., despite rising concerns over antimicrobial resistance. The decision removes a treatment option for resistant infections, potentially worsening clinical outcomes. The move signals a retreat from the antibiotic market, likely due to commercial viability challenges.